Resource Summary Report

Generated by RRID on Aug 3, 2026

ACT-1 [Human thyroid carcinoma]

RRID:CVCL_6291
Type: Cell Line

Proper Citation

RRID:CVCL_6291

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_6291

Proper Citation: RRID:CVCL_6291

Description: Cell line ACT-1 [Human thyroid carcinoma] is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Sex unspecified

Disease: Thyroid gland anaplastic carcinoma

Defining Citation: PMID:12495476, PMID:18713817, PMID:23833040, PMID:26137260, PMID:26680454, PMID:30737244

Comments: Population: Japanese., From: Ohata, Seiji; Tokushima University; Tokushima; Japan.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: ACT-1 [Human thyroid carcinoma]

Synonyms: ACT1

Cross References: BTO:BTO_0004858, cancercelllines:CVCL_6291, CCRID:3101HUMSCSP541, Cosmic:1152115, Cosmic:1239968, Cosmic:2054109, Wikidata:Q54608560

ID: CVCL_6291

Record Creation Time: 20220427T215127+0000

Record Last Update: 20260802T005730+0000

Ratings and Alerts

No rating or validation information has been found for ACT-1 [Human thyroid carcinoma].

No alerts have been found for ACT-1 [Human thyroid carcinoma].

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Kellett MD, et al. (2025) Focal adhesion kinase promotes ribosome biogenesis to drive advanced thyroid cancer cell growth and survival. Frontiers in oncology, 15, 1252544.

Lundgren Mortensen AC, et al. (2025) Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts. Molecular cancer therapeutics, 24(5), 753.

Mackay RP, et al. (2022) YM155 Induces DNA Damage and Cell Death in Anaplastic Thyroid Cancer Cells by Inhibiting DNA Topoisomerase II?? at the ATP-Binding Site. Molecular cancer therapeutics, 21(6), 925.

Marlow LA, et al. (2018) Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts. The Journal of clinical endocrinology and metabolism, 103(9), 3169.